Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 10 von insgesamt 11
- Rekrutierung läuft
A First – in Human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3
Molekulare Marker - Rekrutierung läuftA Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients With Relapsed or Refractory Multiple Myeloma
- Rekrutierung läuftFruquitinib in patients with metastatic colorectal cancer:A prospektive, multicenter, observational study
- Rekrutierung läuftA multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab before SCT in suboptimal responders (GMALL-EVOLVE)
- Rekrutierung läuftPhase 1 study evaluating genetically modified autologous T cells expressing a T cell recepter recognizing a cancer/germline Antigen in patients with recurrent and/or refractory solid Tumors (ACTengine IMA203-101)Target: PRAME
- Rekrutierung läuftBZKF-StudieA Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients with Recurrent and/or Refractory Solid TumorsIndikationen
- Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)
- Gebärmutterkrebs (Uteruskarzinom)
- Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)
- Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)
- Hauttumoren
- Malignes Melanom
- Rekrutierung läuft
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (BRUIN CLL-322)
- Rekrutierung läuftA phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinomaIndikationen
- Rekrutierung läuftA Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refracotroy Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lanalidomide. MonumenTAL-664407564MMY3009
2022-502446-27-00 ( Registry Identifier: EUCT number ) - Rekrutierung läuftProspektives, akademisches, translationales Forschungs-Netzwerk zur Optimierung der onkologischen Gesundheitsversorgung Qualität in der adjuvanten und der fortgeschrittenen/metastasierten Situation: Gesundheitsforschung, Pharmakogenomik, Biomarker, Gesundheitsökonomie PRAEGNANT Brustkrebs: Fortgeschritten/ MetastasierendVERSORGUNGSFORSCHUNGSSTUDIEIndikationen